Clinical Trial Update: Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) [Phase 1, Phase 2]

View source ↗

Summary

ACELYRIN has completed a Phase 1/2 trial evaluating Lonigutamab for Thyroid Eye Disease, with an update highlighting efficacy and safety aspects. The update con…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• Lonigutamab (Lonigutamab)

Snippet

Sponsor: ACELYRIN Inc. | Conditions: Thyroid Eye Disease | Phase 1, Phase 2 | Status: COMPLETED